[Hematopoietic growth factors. Possibilities and limitations]

Area of Science:

• Hematology
• Pharmacology
• Oncology

Context:

• Hematopoietic cell production is regulated by growth factors.
• Granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), and thrombopoiesis-stimulating agents (TSA) are clinically utilized.
• G-CSF and EPO have established roles in managing chemotherapy side effects.

Purpose:

• To review the clinical utility and evidence base for G-CSF, EPO, and TSA.
• To highlight the benefits and limitations of these hematopoietic growth factors.
• To provide recommendations for the future use of TSAs.

Summary:

• G-CSF reduces neutropenia duration but offers modest clinical benefit, with guidelines recommending it for high-risk febrile neutropenia.
• ESAs are alternatives to transfusion for chemotherapy-induced anemia but are linked to increased mortality and adverse events.
• TSAs are newly available for immune thrombocytopenic purpura; their use in chemotherapy-induced thrombocytopenia requires careful evaluation based on G-CSF and ESA experiences.

Impact:

• Informs clinical decision-making regarding the use of hematopoietic growth factors.
• Suggests a cautious approach to implementing new TSAs, emphasizing risk-benefit assessment.
• Highlights the need for ongoing research into the efficacy and safety of these therapeutic agents.